Allergan is buying CoolSculpting provider Zeltiq for $2.48 billion
Botox maker Allergan is spending about $2.48 billion to buy Zeltiq Aesthetics Inc. and its CoolSculpting system for reducing fat.
Allergan said it will pay $56.50 for each share of Zeltiq in a deal it expects to close in the second half of this year. That represents a 14% premium to Zeltiq’s Friday closing price of $49.40. The Pleasanton, Calif., company’s shares jumped 13.2% on Monday to $55.93.
Allergan, based in Dublin, Ireland, said the deal will strengthen an aesthetics business that already includes plastic surgery and regenerative treatments.
Zeltiq’s nonsurgical system cools fat cells to trigger their controlled elimination without affecting the surrounding tissue, according to Allergan.
“The deal makes sense” in large part because it would enable Allergan to sell multiple procedures to individual patients, analyst Jonathan Block of the investment firm Stifel Financial Corp. said in a note to clients Monday.
“The cross-selling opportunity between CoolSculpting and injectables could increase with a bundled sales approach,” Block wrote.
Times staff writer James F. Peltz contributed to this report.
3:15 p.m.: This article was updated with Zeltiq shares’ closing price.
8:10 a.m.: This article was updated with comments from analyst Jonathan Block.
This article was originally published at 7:05 a.m.
Your guide to our clean energy future
Get our Boiling Point newsletter for the latest on the power sector, water wars and more — and what they mean for California.
You may occasionally receive promotional content from the Los Angeles Times.